Cove Street Capital’s Anika Therapeutics ANIK Stock Holding History

Cove Street Capital’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$958K	Buy	101,956 +27,857	+38%	+$266K	1.25%	28
2025 Q2	$784K	Sell	74,099 -803	-1%	-$10.1K	1.15%	30
2025 Q1	$1.13M	Buy	+74,902	New	+$1.25M	1.77%	23
2020 Q2	–	Sell	-20,000	Closed	-$578K	–	76
2020 Q1	$578K	Buy	+20,000	New	+$809K	0.12%	64
2016 Q2	–	Sell	-16,305	Closed	-$729K	–	105
2016 Q1	$729K	Sell	16,305 -318,525	-95%	-$12.9M	0.1%	86
2015 Q4	$12.8M	Sell	334,830 -35,611	-10%	-$1.36M	1.68%	21
2015 Q3	$11.8M	Buy	370,441 +51,728	+16%	+$1.8M	1.56%	23
2015 Q2	$10.5M	Buy	318,713 +307,597	+2,767%	+$11M	1.27%	36
2015 Q1	$458K	Buy	11,116 +100	+0.9%	+$4.04K	0.06%	103
2014 Q4	$449K	Buy	+11,016	New	+$431K	0.07%	100

Other funds holding ANIK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Trigran Investments Northbrook, Illinois $418M AUM 3.34% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Capital Management Glen Allen, Virginia $585M AUM 5.18% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Cove Street Capital's ANIK Position: Q3 2025 in Review

Cove Street Capital increased its Anika Therapeutics (ANIK) stake by 38% in Q3 2025, buying an estimated $266K and bringing the position to 101,956 shares worth $958K. The position accounts for 1.25% of the portfolio, ranked #28.

Cove Street Capital first reported a position in ANIK in Q4 2014 and has held it in 10 quarters since. The position peaked at $12.8M in Q4 2015. 117 funds tracked by Wall St. Rank hold ANIK as of Q3 2025.

Cove Street Capital held 101,956 shares of Anika Therapeutics worth $958K as of Q3 2025.
Cove Street Capital bought 27,857 Anika Therapeutics shares in Q3 2025, an estimated $266K.
Anika Therapeutics made up 1.25% of Cove Street Capital's portfolio in Q3 2025, its #28 holding.
Cove Street Capital first reported a position in Anika Therapeutics in Q4 2014 and has held it in 10 quarters since.
Cove Street Capital's Anika Therapeutics position peaked at $12.8M in Q4 2015.
117 funds tracked by Wall St. Rank held Anika Therapeutics as of Q3 2025.

Based on Cove Street Capital's 13F filing for Q3 2025, filed 13 Nov 2025.